Browse our PLCD1 Proteins (PLCD1)

Human phospholipase C, delta 1 (PLCD1) interaction partners

1. A loss of epidermal PLCdelta1 impairs epidermal barrier function through dysregulation of Ca2 (show CA2 Proteins)+ and p38 mitogen-activated protein kinase (show MAPK14 Proteins) (MAPK (show MAPK1 Proteins)) signaling. This study also reveals a possible link among PLCdelta1 downregulation, p38 MAPK (show MAPK14 Proteins) hyperactivation, and barrier defects in psoriasis-like skin inflammation.

2. PLCD1 acts as a tumour suppressor, by KIF3A (show KIF3A Proteins)-mediated suppression of ERK1/2/beta-catenin (show CTNNB1 Proteins)/MMP7 (show MMP7 Proteins) signalling, at least in part, in breast cancer.

3. Nine of the 32 (28.1%) iCCA (show PRRT2 Proteins) patients had gene mutations at chromosome 3p, totaling 11 mutations across five genes. Those included five (15.6%) BAP1 (show RNF2 Proteins) mutations, two each (6.3%) of CACNA2D3 (show CACNA2D3 Proteins) and RASSF1 (show RASSF1 Proteins) mutations, and one each (3.1%) of ATG7 (show ATG7 Proteins) and PLCD1 mutations. Six (18.8%) cases had concurrent loss of chromosome 3p and gene mutations.

4. The PLCdelta1 negatively regulates autophagy, and PLCdelta1 suppression contributes to the tolerance of CRC cells harboring KRAS mutations to nutrient deprivation and anti-cancer drug treatment.

5. Phospholipase C delta 1 is both a KLF15-regulated gene and a novel repressor of airway smooth muscle hypertrophy.

6. High PLC (show HSPG2 Proteins) delta expression is associated with breast cancer.

7. slow phase of Gi/o-mediated TRPC4 (show TRPC4 Proteins) activation was diminished by inhibiting RhoA (show RHOA Proteins) or enhancing PLCdelta function

8. Neuropeptide Y (show NPY Proteins) decreased PLCD1 expression in HUVECs.

9. PLC (show HSPG2 Proteins)-delta1 and TRPV6 (show TRPV6 Proteins) are critical actor of Ca(2 (show CA2 Proteins)+) homeostasis in CF human bronchial epithelial cells.

10. Ectopic expression of PLCD1 inhibits breast tumor cell proliferation in vivo by inducing apoptosis and suppressed tumor cell migration by regulating cytoskeletal reorganization.

Mouse (Murine) phospholipase C, delta 1 (PLCD1) interaction partners

1. Results show that de novo polarisation of the embryo at the 8-cell stage is directed by phospholipase C (PLC) and protein kinase C (PKC).

2. PLCd1 negatively regulates lipopolysaccharide-induced production of IL-1b (show IL1B Proteins) and Fc gamma receptor (show FCGR1A Proteins)-mediated phagocytosis in macrophages.

3. Data show that phospholipase C delta1 (PLCD1) transfection can induce the apoptosis of CAPAN-1 and BXPC-3 pancreatic cancer cells, arrest the cell cycle in G0 /G1 phase.

4. the Ca(2+) dependence of the interaction between PRIP-C2 and Syt1-C2A was attributed to Ca(2+) binding with Syt1-C2A, but not PRIP-C2, using a series of mutants prepared from both C2 domains.

5. Expression of PLCdelta1 is increased in ALS mouse spinal cord and in neurons from ALS mice. Genetic ablation of this protein in ALS mice significantly increases survival

6. Identification, characterization and regulatory properties of a novel PLCD1 isoform in mouse.

7. Plcd1 and Plcd3 (show PLCd3 Proteins) have synergistic effects on the murine hair follicle in specific regions of the body surface.

8. Loss of phospholipase Cdelta1 from keratinocytes causes features of interleukin-17 (show IL17A Proteins)-associated inflammatory skin diseases.

9. Results suggest that phospholipase C delta(1) is required for skin stem cell lineage commitment.

10. the PLC (show HSPG2 Proteins)-delta1 promoter is under the control of NF-kappaB (show NFKB1 Proteins), which mediates the expression of PLC (show HSPG2 Proteins)-delta due to Abeta42